VYNE Therapeutics (VYNE)
(Delayed Data from NSDQ)
$1.85 USD
+0.01 (0.54%)
Updated Sep 25, 2024 12:00 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
VYNE Therapeutics Inc. (VYNE) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$5.58 | $6.00 | $5.00 | 203.26% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for VYNE Therapeutics Inc. comes to $5.58. The forecasts range from a low of $5.00 to a high of $6.00. The average price target represents an increase of 203.26% from the last closing price of $1.84.
Analyst Price Targets (3 )
Broker Rating
VYNE Therapeutics Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on three recommendations.
Of the three recommendations deriving the current ABR, three are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/12/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
8/14/2024 | LifeSci Capital | Rami Katkhuda | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Stacy Ku | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 3 |
Average Target Price | $5.58 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 87 of 253 |
Current Quarter EPS Est: | -0.24 |
VYNE FAQs
VYNE Therapeutics Inc. (VYNE) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 3 brokerage firms.
The average price target for VYNE Therapeutics Inc. (VYNE) is $5.58. The current on short-term price targets is based on 2 reports.
The forecasts for VYNE Therapeutics Inc. (VYNE) range from a low of $5 to a high of $6. The average price target represents a increase of $203.26 from the last closing price of $1.84.
The current UPSIDE for VYNE Therapeutics Inc. (VYNE) is 203.26%
Based on short-term price targets offered by three analysts, the average price target for VYNE Therapeutics Inc. comes to $5.58. The forecasts range from a low of $5.00 to a high of $6.00. The average price target represents an increase of 203.26% from the last closing price of $1.84.